Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Boris Kallmann"'
Autor:
Matthias Schwab, Andrew Chan, Anna-Katharina Eser, Boris Kallmann, Dieter Pöhlau, Joachim Richter, Torsten B. Wagner, Christoph Grothe
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 641-653 (2024)
Abstract Introduction Treatment adherence is a critical success factor in the disease-modifying therapy (DMT) of multiple sclerosis (MS). The REBISTART study prospectively evaluated adherence in patients using components of a patient support program
Externí odkaz:
https://doaj.org/article/37e20567ddba4394b0fa4dbb255d5e11
Autor:
Heinz Wiendl, Ralf Gold, Thomas Berger, Tobias Derfuss, Ralf Linker, Mathias Mäurer, Orhan Aktas, Karl Baum, Martin Berghoff, Stefan Bittner, Andrew Chan, Adam Czaplinski, Florian Deisenhammer, Franziska Di Pauli, Renaud Du Pasquier, Christian Enzinger, Elisabeth Fertl, Achim Gass, Klaus Gehring, Claudio Gobbi, Norbert Goebels, Michael Guger, Aiden Haghikia, Hans-Peter Hartung, Fedor Heidenreich, Olaf Hoffmann, Boris Kallmann, Christoph Kleinschnitz, Luisa Klotz, Verena I. Leussink, Fritz Leutmezer, Volker Limmroth, Jan D. Lünemann, Andreas Lutterotti, Sven G. Meuth, Uta Meyding-Lamadé, Michael Platten, Peter Rieckmann, Stephan Schmidt, Hayrettin Tumani, Frank Weber, Martin S. Weber, Uwe K. Zettl, Tjalf Ziemssen, Frauke Zipp
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of
Externí odkaz:
https://doaj.org/article/cee55fa870514dd8bb41f4326e4ce63e
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Background: In relapsing–remitting multiple sclerosis (RRMS), ‘no evidence of disease activity’ (NEDA) is regarded as a key treatment goal. The increasing number of treatments allows for individualized treatment optimization in patients with su
Externí odkaz:
https://doaj.org/article/ab987bd903f24cffaff5a5ea2020fa6f
Autor:
Martin S. Weber, Stefan Bittner, Claudio Gobbi, Hayrettin Tumani, Renaud Du Pasquier, Fedor Heidenreich, Ralf A. Linker, Frank Weber, Michael Platten, Martin Stangel, Andrew T. Chan, Heinz Wiendl, Olaf Hoffmann, Thomas Berger, Christian Enzinger, die Multiple Sklerose Therapie Konsensus Gruppe, Elisabeth Fertl, Mathias Mäurer, Orhan Aktas, Uwe K. Zettl, Ralf Gold, Boris Kallmann, Christoph Kleinschnitz, Florian Deisenhammer, Fritz Leutmezer, Jan D. Lünemann, Volker Limmroth, Zoë R. Hunter, Klaus Gehring, Aiden Haghikia, Verena I. Leussink, Franziska Di Pauli, Martin Berghoff, Michael Guger, Luisa Klotz, Tobias Derfuss, Tjalf Ziemssen, Stephan Schmidt, Uta Meyding-Lamadé, Hans-Peter Hartung, Sven G. Meuth, Frauke Zipp, Karl Baum, Achim Gass, Peter Rieckmann, Adam Czaplinski, Norbert Goebels, Andreas Lutterotti
Publikováno v:
Der Nervenarzt
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of
Autor:
Ralf A. Linker, Karl Baum, Michael Guger, Fritz Leutmezer, Stefan Bittner, Martin Stangel, Orhan Aktas, Fedor Heidenreich, Claudio Gobbi, Hans-Peter Hartung, Franziska Di Pauli, Martin Berghoff, Mathias Mäurer, Frauke Zipp, Christoph Kleinschnitz, Thomas Berger, Achim Gass, Elisabeth Fertl, Aiden Haghikia, Verena I. Leussink, Adam Czaplinski, Tobias Derfuss, Norbert Goebels, Martin S. Weber, Christian Enzinger, Uta Meyding-Lamadé, A. Chan, Luisa Klotz, Volker Limmroth, Frank Weber, Boris Kallmann, H. Wiendl, Tjalf Ziemssen, P. Rieckmann, Hayrettin Tumani, Jan D. Lünemann, Klaus Gehring, Uwe K. Zettl, Multiple Sklerose Therapie Konsensus Gruppe, Renaud Du Pasquier, F. Deisenhammer, Olaf Hoffmann, Stephan Schmidt, Andreas Lutterotti, Ralf Gold, Michael Platten, Sven G. Meuth
Publikováno v:
DGNeurologie
Autor:
Sven G Meuth, Antonios Bayas, Boris Kallmann, Ralf Linker, Peter Rieckmann, Mike P Wattjes, Mathias Mäurer, Christoph Kleinschnitz
Publikováno v:
Expert opinion on pharmacotherapy. 23(13)
Introduction: Oral cladribine is a highly effective pulsed selective immune reconstitution therapy licensed for relapsing multiple sclerosis (RMS) since 2017. A full treatment course comprises two treatment cycles given 1 year apart, followed by two
Autor:
Stefan Ries, Ulrich Engelmann, Jennifer S Kullmann, Boris Kallmann, Laura M Quint, Andrew T. Chan
Publikováno v:
Kallmann, Boris A; Ries, Stefan; Kullmann, Jennifer S; Quint, Laura M; Engelmann, Ulrich; Chan, Andrew (2021). Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status. Therapeutic advances in neurological disorders, 14, p. 17562864211005588. Sage 10.1177/17562864211005588
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Therapeutic Advances in Neurological Disorders
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Therapeutic Advances in Neurological Disorders
Background and aims: To investigate effectiveness and safety of teriflunomide (14 mg once daily) in association with age and pre-treatment in unselected MS patients. Methods: Prespecified analysis of a non-interventional, prospective, real-world stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75354bdb730ef84846d2d7012b1034a2
https://boris.unibe.ch/157488/1/Kallmann__2021__Teriflunomide_in_relapsing_remitting_MS.pdf
https://boris.unibe.ch/157488/1/Kallmann__2021__Teriflunomide_in_relapsing_remitting_MS.pdf
Autor:
Ralf A. Linker, Antonios Bayas, Christoph Kleinschnitz, Boris Kallmann, Sven G. Meuth, Peter Rieckmann, Mathias Mäurer
Oral cladribine is a highly effective pulsed selective immune reconstitution therapy licensed for relapsing multiple sclerosis. A full treatment course comprises two treatment cycles given with 1 year of intermission. Further dosing is not routinely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a821c53ff672bd25c658388fef046f56
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85087944395
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85087944395
Autor:
Christoph Kleinschnitz, Boris Kallmann, Frank Weber, Florian Deisenhammer, Hayrettin Tumani, Michael Platten, Luisa Klotz, Fedor Heidenreich, Karl Baum, Uwe K. Zettl, Tjalf Ziemssen, Ralf A. Linker, H. Wiendl, Stephan Schmidt, Sven G. Meuth, Christian Enzinger, Stefan Bittner, Elisabeth Fertl, Verena I. Leussink, Volker Limmroth, Renaud Du Pasquier, Franziska Di Pauli, Michael Guger, Martin Berghoff, Uta Meyding-Lamadé, Achim Gass, Adam Czaplinski, Hans-Peter Hartung, Peter Rieckmann, Norbert Goebels, Klaus Gehring, Aiden Haghikia, Olaf Hoffmann, Mathias Mäurer, Tobias Derfuss, Frauke Zipp, Thomas Berger, Fritz Leutmezer, Martin S. Weber, Orhan Aktas, Ralf Gold, Jan D. Lünemann, Andreas Lutterotti, Andrew T. Chan, Claudio Gobbi
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Wiendl, Heinz; Gold, Ralf; Berger, Thomas; Derfuss, Tobias; Linker, Ralf; Mäurer, Mathias; Aktas, Orhan; Baum, Karl; Berghoff, Martin; Bittner, Stefan; Chan, Andrew; Czaplinski, Adam; Deisenhammer, Florian; Di Pauli, Franziska; Du Pasquier, Renaud; Enzinger, Christian; Fertl, Elisabeth; Gass, Achim; Gehring, Klaus; Gobbi, Claudio; ... (2021). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic advances in neurological disorders, 14, p. 17562864211039648. Sage 10.1177/17562864211039648
Therapeutic Advances in Neurological Disorders
Wiendl, Heinz; Gold, Ralf; Berger, Thomas; Derfuss, Tobias; Linker, Ralf; Mäurer, Mathias; Aktas, Orhan; Baum, Karl; Berghoff, Martin; Bittner, Stefan; Chan, Andrew; Czaplinski, Adam; Deisenhammer, Florian; Di Pauli, Franziska; Du Pasquier, Renaud; Enzinger, Christian; Fertl, Elisabeth; Gass, Achim; Gehring, Klaus; Gobbi, Claudio; ... (2021). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic advances in neurological disorders, 14, p. 17562864211039648. Sage 10.1177/17562864211039648
Therapeutic Advances in Neurological Disorders
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Therapeutic Advances in Neurological Disorders
Therapeutic Advances in Neurological Disorders
Background: In relapsing–remitting multiple sclerosis (RRMS), ‘no evidence of disease activity’ (NEDA) is regarded as a key treatment goal. The increasing number of treatments allows for individualized treatment optimization in patients with su